

# Part II – Colorectal Cancer

## Select Publications

Abrams TA et al. **Patterns of chemotherapy (CT) use in a US-wide population-based cohort of patients (pts) with metastatic colorectal cancer (mCRC).** *Proc ASCO 2012;Abstract 3537.*

**Aflibercept versus placebo in combination with irinotecan and 5-FU in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin based regimen (VELOUR).** NCT00561470

Allegra CJ et al. **Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen.** *Proc ASCO 2012;Abstract 3505.*

Arnold D et al. **Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).** *Proc ASCO 2012;Abstract CRA3503.*

Cartwright TH et al. **Effect of the 12-gene colon cancer assay results on treatment recommendations in patients with stage II colon cancer.** *Proc ASCO 2012;Abstract 3626.*

Faron M et al. **Impact on survival of primary tumor resection in patients with colorectal cancer and unresectable metastasis: Pooled analysis of individual patients' data from four randomized trials.** *Proc ASCO 2012;Abstract 3507.*

Grothey A et al. **Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.** Gastrointestinal Cancers Symposium 2012;Abstract LBA385.

O'Connell M et al. **Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox).** *Proc ASCO 2012;Abstract 3512.*

Pericay C et al. **Phase 2 randomized, noncomparative, open-label, study of aflibercept and modified FOLFOX6 in the first-line treatment of metastatic colorectal cancer (AFFIRM).** ESMO 14<sup>th</sup> World Congress on Gastrointestinal Cancer 2012;Abstract O-0024.

Ross JS et al. **Use of next-generation sequencing (NGS) to detect a novel ALK fusion and a high frequency of other actionable alterations in colorectal cancer (CRC).** *Proc ASCO 2012;Abstract 3533.*

Salazar R et al. **The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.** Gastrointestinal Cancers Symposium 2012;Abstract 678.

Van Cutsem E et al. **Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC).** *Proc ASCO 2012;Abstract 3502.*

Van Cutsem E et al. **Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): Results of a multinational phase 3 trial (EFC10262-VELOUR).** ESMO 13<sup>th</sup> World Congress on Gastrointestinal Cancer 2011;Abstract O-0024.